Welcome to our dedicated page for Ekso Bionics Holdings news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings stock.
Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.
Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.
Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.
For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.
Ekso Bionics announced that Katherine Strausser, Principal Controls Engineer, will participate in an 'AI for Good' webinar titled 'AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility' on Tuesday, November 19 at 10:00 a.m. ET. The session will explore latest exoskeleton technologies and challenges in medical rehabilitation. Katherine, who holds a Ph.D. in Mechanical Engineering and is one of the original inventors of the EksoNR device, specializes in controls systems for robotics and human-exoskeleton interaction.
Ekso Bionics Holdings (Nasdaq: EKSO), a leader in medical and industrial exoskeleton technology, has announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York. CEO Scott Davis and CFO Jerome Wong will conduct one-on-one meetings with institutional investors during the event. Interested investors should contact their Craig-Hallum representative to schedule meetings.
Ekso Bionics (NASDAQ: EKSO) reported Q3 2024 financial results with revenue of $4.1 million, down from $4.6 million in Q3 2023. The company sold 33 EksoHealth devices and achieved a gross margin of 53.5%. Net loss narrowed to $2.1 million ($0.10 per share) from $3.4 million ($0.24 per share) year-over-year. A significant milestone was reached with initial CMS reimbursement approval for Ekso Indego Personal. The company completed an offering raising $5.0 million, ending Q3 with $8.3 million cash on hand.
Ekso Bionics (NASDAQ: EKSO), a leader in exoskeleton technology, has announced the pricing of a $6.0 million underwritten public offering. The offering consists of 6,000,000 total units and pre-funded units, priced at $1.00 per unit and $0.999 per pre-funded unit. Each unit includes common stock and warrants, while pre-funded units contain pre-funded warrants and additional warrants. The company plans to use the net proceeds for general corporate purposes, including:
- Growth and expansion of its EksoHealth segment
- Research and development activities
- Selling, general and administrative costs
- Pursuing strategic initiatives, including potential acquisitions
- Meeting working capital needs
The offering is expected to close around September 3, 2024, with Craig-Hallum acting as the sole managing underwriter.
Ekso Bionics (Nasdaq: EKSO) announced the receipt of initial CMS reimbursement for its Ekso Indego Personal exoskeleton device. The Medicare program paid a lump sum of $91,032 based on the HCPCS code K1007, effective April 1, 2024. This marks the first reimbursement for Medicare beneficiaries since Ekso received final payment determination.
The company launched the EksoHealth Personal Program to help patients access personal exoskeletons through a screening process. Ekso's clinical customers are actively participating in the program, identifying appropriate patients and offering training for home and community use. Ekso plans to work with Medicare Advantage plans and commercial insurers later in 2024, potentially increasing the addressable market for Ekso Indego Personal.
Ekso Bionics (NASDAQ: EKSO) reported record quarterly sales of $5.0 million in Q2 2024, a 5% increase from Q2 2023. The company sold 37 EksoHealth devices and achieved a gross margin of 53%. Key highlights include:
- Initial Medicare claims for Ekso Indego Personal pending reimbursement
- Net loss of $2.4 million ($0.13 per share), improved from $4.2 million loss in Q2 2023
- Reduced operating expenses across sales, marketing, R&D, and G&A
- Cash on hand at $5.9 million as of June 30, 2024
CEO Scott Davis expressed optimism about increased demand for Ekso Indego Personal following Medicare reimbursement mechanisms. The company aims to expand its reach to individuals with spinal cord injuries and continue executing its commercial strategy for growth.
Ekso Bionics Holdings, Inc. (EKSO), a leader in exoskeleton technology for medical and industrial use, has announced its plans to release financial and business results for the second quarter of 2024. The results will be made public after the close of trading on Monday, July 29, 2024. Following the release, management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
Investors can access the live webcast of the event through the "Investors" section of the company's website. For those preferring to listen via phone, domestic callers can dial 877-407-3036, while international callers should use 201-378-4919. A replay of the webcast will be available on the company's website for one month after the call.
Ekso Bionics has announced a research partnership with Shepherd Center, a leading rehabilitation hospital in Atlanta. The collaboration aims to integrate EksoNR and Ekso Indego devices into rehabilitation and community settings to enhance patient quality of life. Ekso and Shepherd Center will co-develop a research and training program for these devices, focusing on best practices for their clinical and individual use. This initiative follows the Centers for Medicare & Medicaid Services' recent decision to provide reimbursement for the Ekso Indego Personal device, increasing accessibility for spinal cord injury patients. Shepherd Center's expertise in spinal cord injuries will play a key role in evaluating the benefits of exoskeleton technology throughout the care continuum.
Ekso Bionics has appointed Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. Scher brings extensive healthcare experience, having served as an Executive Advisor to the U.S. Department of Veterans Affairs (VA). She led the VA Secretary's Center for Strategic Partnerships and implemented over $250 million in programs for veterans. Currently, she is a Senior Advisor at the Milken Institute and serves on multiple boards. Scher's appointment aligns with Ekso's recent Medicare reimbursement pricing for the Ekso Indego Personal, which aids in patient rehabilitation.
Ekso Bionics Holdings, an industry leader in exoskeleton technology, will feature the Ekso Indego Personal on 'Health Uncensored' with Dr. Drew Pinsky on Fox Business News. The episode will air on May 12, showcasing the device's user-reported benefits and advanced technology. The Ekso Indego Personal is a powered exoskeleton designed to help patients with mobility impairments walk independently, offering a potentially life-changing solution for individuals previously confined to wheelchairs.
FAQ
What is the current stock price of Ekso Bionics Holdings (EKSO)?
What is the market cap of Ekso Bionics Holdings (EKSO)?
What does Ekso Bionics Holdings, Inc. do?
Where is Ekso Bionics headquartered?
What are the main segments of Ekso Bionics?
What does the EksoHealth segment specialize in?
What does the EksoWorks segment focus on?
How has Ekso Bionics impacted people with paralysis?
In which regions does Ekso Bionics operate?
How can I get in touch with Ekso Bionics for investor relations?
What innovations has Ekso Bionics brought to the industrial market?
How does Ekso Bionics contribute to physical rehabilitation?
